Indian biopharmaceutical company Vyome Therapeutics Inc. has secured 154 crore rupees ($22 million) in a Series D round of funding.
Vyome plans to use the funds to develop its lead molecule, VB 1953, and part of the funds to facilitate a secondary transaction.
The round was led by new backers Iron Pillar with participation from existing backers including Perceptive Advisors, Romulus Capital and Kalaari Capital.
In August 2016, Vyome bagged $14 million in a Series C funding round.